Method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AssigneeViralytics Limited
InventorDarren R. Shafren
Life of this patent
Estimating the term…
Abstract
There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.
Claims33
A method of treating abnormal cells in a mammal comprising administering to the mammal an effective amount of a virus capable of infecting the abnormal cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells.
(canceled)
(canceled)
9-12. (canceled)
(canceled)
17-32. (canceled)
A method of screening abnormal cells for determining whether the cells are susceptible to viral induced cell death, comprising the steps of:
- (a) providing the abnormal cells;
- (b) adding to the cells an effective amount of a virus which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells;
- optionally (i) wherein the cell adhesion molecule is ICAM-1, (ii) wherein the complement regulatory protein is DAF;
- (c) incubating the abnormal cells in the presence of the virus for a period of time;
- and
- (d) determining whether the virus has infected and caused death of at least some of the abnormal cells.
34-37. (canceled)
(canceled)
41-43. (canceled)
45-54. (canceled)
A method of screening a virus for ability to infect and cause death of abnormal cells, comprising the steps of:
- (a) selecting a virus which recognises at least one of a cell adhesion molecule of the (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells;
- optionally (i) wherein the cell adhesion molecule is ICAM-1, or (ii) wherein the complement regulatory protein is DAF;
- (b) incubating the selected said virus with a sample of the abnormal cells for a period of time;
- and
- (c) determining whether the selected said virus causes death of at least some of the abnormal cells;
- optionally wherein the abnormal cells are cells of a malignancy selected from the group consisting of a malignancy of the skin, prostate cancer, stomach cancer, breast cancer and colon cancer.
57-61. (canceled)
63-77. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a virus capable of infecting abnormal cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells;
- optionally (i) wherein the cell adhesion molecule is ICAM-1, or (ii) wherein the complement regulatory protein is DAF.
79-84. (canceled)
86-88. (canceled)
90-129. (canceled)
Dependencies are inferred from the claim text.